medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2007, Number 4

<< Back Next >>

Acta Med 2007; 5 (4)

The current state of the occlusive peripheral arterial disease (OPAD)

Águila MR, Marquina RM

Language: Spanish
References: 43
Page: 187-196
PDF size: 167.38 Kb.


ABSTRACT

There are three types of manifestation of Peripheral Arterial Disease (PAD): Intermittent Claudication, Critical limb ischemia or Acute limb ischemia. Worldwide disease prevalence based on objective testing has been evaluated in several epidemiologic studies and is in the15 to 20% in persons over 70 years. The most common symptoms related are: from muscle pain at walking to non healing ulcer after 2 weeks of treatment. The risk factors like: Smoking, Diabetes Mellitus and Dyslipidemia must be strictly controlled to delay the atherosclerotic process in the peripheral arteries. Actually the management can be separated in: prophylactic, pharmacological and classical surgery or endovascular procedures. The Vascular Surgeon must be the head of the team in the treatment of this kind of patients to offer the best choice for management


REFERENCES

  1. Norgren L, Hiatt WR, Dormandy JA et al. Inter-Society Consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007; 45: S5A-67.

  2. TASC. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Eur J Vasc Endovasc Surg 2000; 19(Suppl A): Si-xxviii. S1-250.

  3. TASC. Management of peripheral arterial disease (PAD) TransAtlantic Intersociety Consensus (TASC). J Vasc Surg 2000; 31(1 part 2): S1-287.

  4. TASC. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Int Angiol 2000; 19(1 Suppl. 1): I-XXIV. 1-304.

  5. Clement DL, Boccalon H, Dormandy J, Durand-Zaleski I, Fowkes G, Brown T. A clinical approach to the management of the patient with coronary (Co) and/or carotid (Ca) artery disease who presents with leg ischemia (Lis). Int Angiol 2000; 19(2): 97-125.

  6. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation 2004; 110(6): 738-743.

  7. Fowkes FG, Housley E, Cawood EH, MacIntyre CC, Ruckley CV, Prescott RJ. Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20(2): 384-392.

  8. Hirsch A, Criqui M, reta-Jacobson D, Regensteiner J, Creager M, Olin J et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286(11): 1317-1324.

  9. Criqui MH, Vargas V, Denenberg JO, Ho E, Allison M, Langer RD et al. Ethnicity and peripheral arterial disease: the San Diego Population Study. Circulation 2005; 112(17): 2703-2707.

  10. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141(6): 421-431.

  11. Muntner P, Wildman RP, Reynolds K, Desalvo KB, Chen J, Fonseca V. Relationship between HbA1c level and peripheral arterial disease. Diabetes Care 2005; 28(8): 1981-1987.

  12. ADA Peripheral arterial disease in people with diabetes. Diabetes Care 2003; 26(12): 3333-3341.

  13. Senti M, Nogues X, Pedro-Botet J, Rubies-Prat J, Vidal-Barraquer F. Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes. Circulation 1992; 85(1): 30-36.

  14. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285(19): 2481-2485.

  15. O’Hare AM, Vittinghoff E, Hsia J, Shlipak MG. Renal insufficiency and the risk of lower extremity peripheral arterial disease: results from the Heart and Estrogen/Progestin Replacement Study (HERS). J Am Soc Nephrol 2004; 15(4): 1046-1051.

  16. McDermott MM, Criqui MH, Greenland P, Guralnik JM, Liu K, Pearce WH et al. Leg strength in peripheral arterial disease: associations with disease severity and lower-extremity performance. J Vasc Surg 2004; 39(3): 523-530

  17. Hallet JW et al. Comprehensive vascular and endovascular surgery. Elsevier. 2004: 65-78.

  18. Norgren et al. Management for claudication. Transatlantic Society Consensus TASC II. Jour Vasc Surg 2007; 45(1. Sup): 27-29.

  19. 19.Hirsch et al. ACC/AHA Practice guidelines for the management of peripheral artery disease. Circulation 2006; 113: 1493-1494.

  20. RegensteinerJ et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002; 50(12): 1939-1946.

  21. Dawson D et al. Comparison of cilostazol and pentoxifyline for treating intermittent claudication. Am J Med 2000; 109(7): 523-530.

  22. Mannava et al. Current management of peripheral arterial occlusive disease: A Review of pharmacologic agents and other interventions. Am J Cardiovasc Drugs 2007; 7(1): 59-66.

  23. Hiatt W et al. Propionyl-L- carnitine improves exercise performance and functional status in patients with claudication. Am J Med 2001; 110 (8): 616-622.

  24. Hood SC et al. Management of intermittent claudication with pentoxifyline: meta-analysis of randomized controlled trials. CMAJ 1996; 155(8): 1053-1059.

  25. Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MG et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002; 346(23): 1800-1806.

  26. Lowensteyn I, Coupal L, Zowall H, Grover SA. The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease. J Cardiopulm Rehabil 2000; 20(3): 147-155.

  27. Lamy A, Yusuf S, Pogue J, Gafni A. Cost implications of the use of ramipril in high-risk patients based on the heart outcomes prevention evaluation (HOPE) study. Circulation 2003; 107(7): 960-965.

  28. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina–summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003; 41(1): 159-168.

  29. Rundback JH, Sacks D, Kent KC, Cooper C, Jones D, Murphy T et al. Guidelines for the reporting of renal artery revascularization in clinical trials. J Vasc Interv Radiol 2003; 14(9 Pt 2): S477-492.

  30. Labs KH, Dormandy JA, Jaeger KA, Stuerzebecher C, Hiatt WR. Transatlantic conference on clinical trial guidelines in PAOD (Peripheral arterial occlusive disease) clinical trial methodology. Eur J Vasc Endovasc Surg 1999; 18(3): 253-265.

  31. Kieffer E, Bahnini A, Mouren X, Gamand S. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the naftidrofuryl clinical ischemia study (NCIS). Int Angiol 2001; 20(1): 58-65.

  32. Spengel F, Clement D, Boccalon H, Liard F, Brown T, Lehert P. Findings of the naftidrofuryl in quality of life (NIQOL) European study program. Int Angiol 2002; 21(1): 20-27.

  33. Mohler E III, Hiatt W, Creager M. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003; 108(12): 1481-1486.

  34. Moher D, Pham B, Ausejo M, Saenz A, Hood S, Barber G. Pharmacological management of intermittent claudication: a meta-analysis of randomized trials. Drugs 2000; 59(5): 1057-1070.

  35. Maxwell AJ, Anderson BE, Cooke JP. Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of Heart Bar. Vasc Med 2000; 5(1): 11-19

  36. Lievre M, Morand S, Besse B, Fiessinger J, Boissel J. Oral beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et claudication intermittent (BERCI) Research group. Circulation 2000; 102(4): 426-431.

  37. de Backer T, Vander Stichele R, Warie H, Bogaert M. Oral vasoactive medication in intermittent claudication: utile or futile? Eur J Clin Pharmacol 2000; 56(3): 199-206.

  38. Lederman R, Mendelsohn F, Anderson R, Saucedo J, Tenaglia A, JB H et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomized trial. Lancet 2002; 359(9323): 2053-2058.

  39. Reiber GE, Vileikyte L, Boyko EJ del Aguila M, Smith DG, Lavery LA et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 1999; 22(1): 157-162.

  40. Smith I, Franks PJ, Greenhalgh RM, Poulter NR, Powell JT. The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischaemia. Eur J Vasc Endovasc Surg 1996; 11(4): 402-408.

  41. Nabuurs-Franssen MH, Sleegers R, Huijberts MS, Wijnen W, Sanders AP, Walenkamp G et al. Total contact casting of the diabetic foot in daily practice: a prospective follow-up study. Diabetes Care 2005; 28(2): 243-247.

  42. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26(3): 517-38.

  43. Kuukasjarvi P, Salenius J. Perioperative outcome of acute lower limb ischaemia on the basis of the national vascular registry. The Finnvasc Study Group. Eur J Vasc Surg 1994; 8: 578-583.




2020     |     www.medigraphic.com